Premium
Methyl‐CCNU, doxorubicin, and cis‐diaminedichloroplatinum II in the management of recurrent and metastatic squamous carcinoma of the cervix
Author(s) -
Masterson Byron J.,
Carlson John A.,
Day Thomas G.,
Allegra Joseph C.,
Woodcock Thomas M.,
Greenberg Richard A.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840715)54:2<211::aid-cncr2820540206>3.0.co;2-e
Subject(s) - medicine , cervix , squamous carcinoma , doxorubicin , oncology , carcinoma , chemotherapy , cancer
Twenty‐three patients with recurrent unresectable carcinoma of the cervix or distant metastasis at initial presentation were treated with methyl‐CCNU (175 mg/m 2 ) and doxorubicin (45 mg/m 2 ) on day 1 and Cis‐diaminedichloroplatinum II (90 mg/m 2 ) on day 22 of a 42‐day treatment cycle. Twenty‐two patients had squamous carcinoma and 1 had adenosquamous carcinoma. There were two complete responses (CR), five partial responses (PR) (>50% tumor reduction, >3‐month duration), four patients with stable disease (<50% reduction, >3‐month duration), and 12 patients who had tumor progression. One CR has been maintained > 28 months, and the other >8 months. Total CR and PR was 7 of 23 (30.4%). Three responses occurred among 15 patients (20%) who had cancer primarily confined to the pelvis, while 4 of 8 patients (50%) with distant metastasis responded. During the initial 2 cycles of chemotherapy, 12 patients had myelosuppression, defined as a leukocytes <3000/mm 3 , granulocytes <1,000/mm 3 , or platelets <100,000/mm 3 . There were no treatment‐related deaths.